Significant Revenue Growth
Biofrontera reported a 34% increase in total revenues for the second quarter of 2024 compared to the second quarter of 2023, with revenues reaching $7.8 million.
Successful Cost Management
Total operating expenses decreased to $12.9 million in Q2 2024 from $14.5 million in Q2 2023. SG&A expenses also decreased to $7.9 million from $11.5 million in the same period.
Debt Reduction and Financial Stability
Biofrontera paid down all outstanding debt in the second quarter and increased cash and cash equivalents to $4.4 million as of June 30, 2024, compared to $1.3 million at the end of 2023.
Introduction of RhodoLED XL Lamp
The company began sales of the FDA-approved RhodoLED XL lamp on June 10, 2024, which is expected to enhance treatment options for actinic keratosis.
Improved Product Offering
The FDA approved a new formulation of Ameluz lacking propylene glycol, improving tolerability and potentially extending shelf life.